Financhill
Buy
58

VCYT Quote, Financials, Valuation and Earnings

Last price:
$30.34
Seasonality move :
16.83%
Day range:
$29.30 - $30.71
52-week range:
$19.71 - $47.32
Dividend yield:
0%
P/E ratio:
99.03x
P/S ratio:
5.18x
P/B ratio:
1.97x
Volume:
1.3M
Avg. volume:
981.5K
1-year change:
47.59%
Market cap:
$2.3B
Revenue:
$445.8M
EPS (TTM):
$0.30

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VCYT
Veracyte
$111M $0.20 14.14% -93.75% $42.20
APDN
Applied DNA Sciences
$1.2M -$3.00 27.47% -98.87% --
FONR
Fonar
-- -- -- -- --
OCX
OncoCyte
$126.8K -$0.25 -27.97% -77.88% $4.42
PRPH
ProPhase Labs
$2.5M -$0.18 -32.58% -48.57% $13.80
XWEL
XWELL
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VCYT
Veracyte
$29.71 $42.20 $2.3B 99.03x $0.00 0% 5.18x
APDN
Applied DNA Sciences
$0.91 -- $1M -- $0.00 0% 0.06x
FONR
Fonar
$12.30 -- $77.9M 10.70x $0.00 0% 0.78x
OCX
OncoCyte
$3.10 $4.42 $88.7M -- $0.00 0% 21.53x
PRPH
ProPhase Labs
$0.32 $13.80 $13.5M -- $0.00 0% 0.98x
XWEL
XWELL
$0.78 -- $4.1M -- $0.00 0% 0.11x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VCYT
Veracyte
-- 3.551 -- 4.27x
APDN
Applied DNA Sciences
-- 5.301 -- 4.28x
FONR
Fonar
0.03% 1.233 0.07% 10.85x
OCX
OncoCyte
-- -1.798 -- 1.41x
PRPH
ProPhase Labs
31.06% -4.436 37.21% 1.12x
XWEL
XWELL
-- -0.848 -- 1.72x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VCYT
Veracyte
$78.8M $6M 2.14% 2.14% 2.9% $20.4M
APDN
Applied DNA Sciences
$684.1K -$3M -113.07% -113.07% -247.7% -$3.4M
FONR
Fonar
$9.7M $2.4M 4.95% 4.95% 11.92% $1.5M
OCX
OncoCyte
$595K -$5.4M -581.11% -581.11% -2253.1% -$5.6M
PRPH
ProPhase Labs
-$165K -$7.9M -47.22% -59.59% -252.29% -$4.2M
XWEL
XWELL
$2.1M -$4.6M -71.82% -71.82% -54.82% -$3.8M

Veracyte vs. Competitors

  • Which has Higher Returns VCYT or APDN?

    Applied DNA Sciences has a net margin of 4.31% compared to Veracyte's net margin of -220.57%. Veracyte's return on equity of 2.14% beat Applied DNA Sciences's return on equity of -113.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    VCYT
    Veracyte
    66.39% $0.06 $1.2B
    APDN
    Applied DNA Sciences
    57.17% -$28.00 $12.5M
  • What do Analysts Say About VCYT or APDN?

    Veracyte has a consensus price target of $42.20, signalling upside risk potential of 42.04%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 164735.17%. Given that Applied DNA Sciences has higher upside potential than Veracyte, analysts believe Applied DNA Sciences is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    VCYT
    Veracyte
    7 2 1
    APDN
    Applied DNA Sciences
    0 1 0
  • Is VCYT or APDN More Risky?

    Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.491%.

  • Which is a Better Dividend Stock VCYT or APDN?

    Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VCYT or APDN?

    Veracyte quarterly revenues are $118.6M, which are larger than Applied DNA Sciences quarterly revenues of $1.2M. Veracyte's net income of $5.1M is higher than Applied DNA Sciences's net income of -$2.6M. Notably, Veracyte's price-to-earnings ratio is 99.03x while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 5.18x versus 0.06x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VCYT
    Veracyte
    5.18x 99.03x $118.6M $5.1M
    APDN
    Applied DNA Sciences
    0.06x -- $1.2M -$2.6M
  • Which has Higher Returns VCYT or FONR?

    Fonar has a net margin of 4.31% compared to Veracyte's net margin of 7.87%. Veracyte's return on equity of 2.14% beat Fonar's return on equity of 4.95%.

    Company Gross Margin Earnings Per Share Invested Capital
    VCYT
    Veracyte
    66.39% $0.06 $1.2B
    FONR
    Fonar
    39.03% $0.29 $159M
  • What do Analysts Say About VCYT or FONR?

    Veracyte has a consensus price target of $42.20, signalling upside risk potential of 42.04%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    VCYT
    Veracyte
    7 2 1
    FONR
    Fonar
    0 0 0
  • Is VCYT or FONR More Risky?

    Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison Fonar has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.30600000000001%.

  • Which is a Better Dividend Stock VCYT or FONR?

    Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VCYT or FONR?

    Veracyte quarterly revenues are $118.6M, which are larger than Fonar quarterly revenues of $25M. Veracyte's net income of $5.1M is higher than Fonar's net income of $2M. Notably, Veracyte's price-to-earnings ratio is 99.03x while Fonar's PE ratio is 10.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 5.18x versus 0.78x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VCYT
    Veracyte
    5.18x 99.03x $118.6M $5.1M
    FONR
    Fonar
    0.78x 10.70x $25M $2M
  • Which has Higher Returns VCYT or OCX?

    OncoCyte has a net margin of 4.31% compared to Veracyte's net margin of -2255.11%. Veracyte's return on equity of 2.14% beat OncoCyte's return on equity of -581.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    VCYT
    Veracyte
    66.39% $0.06 $1.2B
    OCX
    OncoCyte
    40.04% -$1.93 -$12.3M
  • What do Analysts Say About VCYT or OCX?

    Veracyte has a consensus price target of $42.20, signalling upside risk potential of 42.04%. On the other hand OncoCyte has an analysts' consensus of $4.42 which suggests that it could grow by 42.47%. Given that OncoCyte has higher upside potential than Veracyte, analysts believe OncoCyte is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    VCYT
    Veracyte
    7 2 1
    OCX
    OncoCyte
    1 2 0
  • Is VCYT or OCX More Risky?

    Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison OncoCyte has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.749%.

  • Which is a Better Dividend Stock VCYT or OCX?

    Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VCYT or OCX?

    Veracyte quarterly revenues are $118.6M, which are larger than OncoCyte quarterly revenues of $1.5M. Veracyte's net income of $5.1M is higher than OncoCyte's net income of -$33.5M. Notably, Veracyte's price-to-earnings ratio is 99.03x while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 5.18x versus 21.53x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VCYT
    Veracyte
    5.18x 99.03x $118.6M $5.1M
    OCX
    OncoCyte
    21.53x -- $1.5M -$33.5M
  • Which has Higher Returns VCYT or PRPH?

    ProPhase Labs has a net margin of 4.31% compared to Veracyte's net margin of -209.38%. Veracyte's return on equity of 2.14% beat ProPhase Labs's return on equity of -59.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    VCYT
    Veracyte
    66.39% $0.06 $1.2B
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
  • What do Analysts Say About VCYT or PRPH?

    Veracyte has a consensus price target of $42.20, signalling upside risk potential of 42.04%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 4175.09%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    VCYT
    Veracyte
    7 2 1
    PRPH
    ProPhase Labs
    0 0 0
  • Is VCYT or PRPH More Risky?

    Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.472, suggesting its less volatile than the S&P 500 by 147.175%.

  • Which is a Better Dividend Stock VCYT or PRPH?

    Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VCYT or PRPH?

    Veracyte quarterly revenues are $118.6M, which are larger than ProPhase Labs quarterly revenues of $3.1M. Veracyte's net income of $5.1M is higher than ProPhase Labs's net income of -$6.6M. Notably, Veracyte's price-to-earnings ratio is 99.03x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 5.18x versus 0.98x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VCYT
    Veracyte
    5.18x 99.03x $118.6M $5.1M
    PRPH
    ProPhase Labs
    0.98x -- $3.1M -$6.6M
  • Which has Higher Returns VCYT or XWEL?

    XWELL has a net margin of 4.31% compared to Veracyte's net margin of -56.4%. Veracyte's return on equity of 2.14% beat XWELL's return on equity of -71.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    VCYT
    Veracyte
    66.39% $0.06 $1.2B
    XWEL
    XWELL
    24.38% -$0.99 $14.8M
  • What do Analysts Say About VCYT or XWEL?

    Veracyte has a consensus price target of $42.20, signalling upside risk potential of 42.04%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 797.44%. Given that XWELL has higher upside potential than Veracyte, analysts believe XWELL is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    VCYT
    Veracyte
    7 2 1
    XWEL
    XWELL
    0 0 0
  • Is VCYT or XWEL More Risky?

    Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

  • Which is a Better Dividend Stock VCYT or XWEL?

    Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VCYT or XWEL?

    Veracyte quarterly revenues are $118.6M, which are larger than XWELL quarterly revenues of $8.4M. Veracyte's net income of $5.1M is higher than XWELL's net income of -$4.8M. Notably, Veracyte's price-to-earnings ratio is 99.03x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 5.18x versus 0.11x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VCYT
    Veracyte
    5.18x 99.03x $118.6M $5.1M
    XWEL
    XWELL
    0.11x -- $8.4M -$4.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Adobe Stock a Bargain With AI Tools Driving Growth?
Is Adobe Stock a Bargain With AI Tools Driving Growth?

The share price of American computer software company Adobe (NASDAQ:ADBE)…

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
62
RGC alert for May 2

Regencell Bioscience Holdings [RGC] is down 22.08% over the past day.

Buy
65
MYRG alert for May 2

MYR Group [MYRG] is up 5.11% over the past day.

Sell
35
FTAI alert for May 2

FTAI Aviation [FTAI] is up 3.53% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock